Eisai completes rolling submission to US FDA for LEQEMBI IQLIK supplemental biologics license application Read more
Early Alzheimer’s patients continue to benefit from 4 yrs of LEQEMBI(R) (lecanemab-irmb) Therapy, new clinical data presented at AAIC Read more
Eisai and Biogen’s Leqembi launch in China marks turning point in Alzheimer’s treatment, says GlobalData Read more
USFDA accepts Eisai’s sBLA and grants priority review for approval of LEQEMBITM Alzheimer’s treatment Read more